Area of research
Public Health, Environmental and Occupational Health · Pediatrics, Perinatology and Child Health
Research interest
Research interests include Medicine, Internal medicine, Lymphoblastic Leukemia, Oncology, Biology, and Leukemia.
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children
Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children’s Oncology Group study
Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia
Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children’s Oncology Group Report
Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials
Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group
Poverty and Relapse Risk in Children with Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL03N1 Report
Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932
The genomic landscape of pediatric acute lymphoblastic leukemia
Body mass index during maintenance therapy and relapse risk in children with acute lymphoblastic leukemia: A Children's Oncology Group report
Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932
Targetable kinase gene fusions in high-risk B-ALL: a study from the Children’s Oncology Group
Longitudinal analysis of quality‐of‐life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial
Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children’s oncology group (COG) clinical trials
Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia
Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic Leukemia
Detection of Minimal Residual Disease in B Lymphoblastic Leukemia by High-Throughput Sequencing of <i>IGH</i>
Pharmacokinetic and Pharmacodynamic Properties of Calaspargase Pegol <i>Escherichia coli</i> L-Asparaginase in the Treatment of Patients With Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Study AALL07P4